First patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers

Xintela announces that the first patient has been dosed in the company's clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg ulcers. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela.

Xintela's ongoing Phase I/IIa clinical study in patients with difficult-to-heal venous leg ulcers is a placebo-controlled, randomized study. Twelve patients with difficult-to-heal venous leg ulcers will receive one dose of XSTEM or placebo applied to the wound and will then be followed weekly for ten weeks. The primary goal of the study is to show that the treatment is safe but also that XSTEM has a positive effect on wound healing.

"It is gratifying that the first patient in the study has now been dosed. This is a patient group that is difficult to recruit and we are very pleased that our investments in additional clinics and amendments in the study protocol are showing results. We are now hoping for a successful recruitment of the remaining patients", says Camilla Wennersten, Xintela's Director Clinical Development.

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser is Carnegie Investment Bank AB (publ).

Attachments

First patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers